Studies on the Specific Fibrinolytic Effect of Human Extrinsic (Tissue-Type) Plasminogen Activator in Human Blood and in Various Animal Species in Vitro

Summary

Human extrinsic (tissue-type) plasminogen activator (EPA) was highly purified from the culture fluid of a human melanoma cell line, both as a one-chain or as a two-chain molecule. Its specific fibrinolytic effect on human whole blood clots or plasma clots with different degrees of fibrin crosslinking was evaluated in an in vitro system, composed of a ¹²⁵I-fibrin labeled clot, hanging in circulating human plasma. After infusion of EPA (30 IU per ml over 3 hrs), non-crosslinked clots lysed more extensively (75-100 percent in 5 hrs) than totally-crosslinked clots (50-65 percent), and no difference was found between one-chain or two-chain EPA. The extent of lysis of totally-crosslinked human or animal plasma clots hanging in autologous plasma induced by EPA varied markedly from one species to the other. When 90 IU of EPA were infused over 3 hrs, crosslinked human plasma clots dissolved for over 95 percent within 5 hrs. Under comparable conditions, the degree of lysis was 80 percent in primate plasma (cynomolgus fascicularis), 60 percent in cat and rabbit plasma, 30 percent in dog plasma and only 10 percent in rat plasma. Systemic activation of the fibrinolytic system in the circulating plasmas was minor and dose-dependent in all species, but complete fibrinogen breakdown was not observed in any species following infusion of up to 90 IU EPA per ml plasma.

It is concluded that the human system is more susceptible to EPA induced fibrinolysis than the other animal systems which were investigated, and that even totally-crosslinked clots can be lysed after infusion of EPA.

Keywords

Extrinsic (tissue-type) plasminogen activator - Thrombolysis of crosslinked clots - Thrombolytic/fibrinogenolytic ratio - Species variability

• References

• 1 Irfan M. Fibrinolytic activity in animals of different species. J Exp Physiol 1968; 53: 374-380
• 2 Jenks RL, Astrup T. Euglobulin fibrinolysis in several species and the effect of some synthetic agents. In: “Progress in chemical fibrinolysis and thrombolysis, Vol 3”. Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (eds.) p 111-114 Raven Press; New York: 1978
• 3 Summaria L, Arzadon L, Bemabe P, Robbins KC. The interaction of streptokinase with human, cat, dog, and rabbit plasminogen. The fragmentation of streptokinase in the equimolar plasminogen-strep-tokinase complexes J Biol Chem 1974; 249: 4760-4768
• 4 Rijken DC, Collen D. Purification and characterization of plasminogen activator secreted by human melanoma cells in culture. J Biol Chem 1981; 256: 7035-7041
• 5 Matsuo O, Rijken DC, Collen D. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator in vitro. Thromb Haemostas 1981; 45: 225-229
• 6 Matsuo O, Rijken DC, Collen D. Thrombolytic properties of human tissue plasminogen activator in rabbits with an experimental pulmonary embolus. Nature 1981; 291: 590-591
• 7 Korninger C, Matsuo O, Suy R, Stassen JM, Collen D. Thrombolytic properties of purified tissue plasminogen activator in a dog femoral vein thrombosis model. VIIIth Int Congress on Thrombosis and Haemostasis. Toronto 191: Abstract Nr 659
• 8 Kominger C, Collen D. Inhibition of human tissue plasminogen activator in human plasma: no evidence for a specific antiactivator. VIIIth Int Congress on Thrombosis and Haemostasis. Toronto: 1981. Abstract Nr 882
• 9 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Arkiv Kemi 1956; 10: 415-428
• 10 McFarlane AG. Efficient trace-labelling of proteins with iodine. Nature 1958; 182: 53
• 11 Fenton JW, Fasco MJ, Stackrow AB, Aronson DL, Young AM, Finlayson JS. Human thrombins. Production, evaluation and properties of α-thrombin J Biol Chem 1977; 252: 3587-3598
• 12 Gaffney PJ, Lane DA, Brasher M. Soluble high molecular weight E fragments in the plasmin-induced degradation products of crosslinked human fibrin. Cli Sci Mol Med 1975; 49: 149-156
• 13 Weber K, Osborn M. The reliability of molecular weight determinations by dodecyl sulphate polyacrylamide electrophoresis. J Biol Chem 1969; 244: 4406-4412
• 14 Vermylen C, De Vreker R, Verstraete M. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT-test). Clin Chim Acta 1963; 8: 418-424
• 15 Edy J, Collen D, Verstraete M. Quantitation of the plasma protease inhibitor antiplasmin with the chromogenic substrate S-2251. In: “Progress in chemical fibrinolysis and thrombolysis, Vol 3”. Davidson JF, Samama MM, Desnoyers PC. (eds.) p 315-322 Raven Press; New York: 1978
• 16 Friberger P, Knös M. Plasminogen determination in human plasma. In: “Chromogenic peptide substrates”. Scully MF, Kakkar W. (eds.) p 128-140 Churchill Livingstone, Edinburgh: 1979
• 17 Gaffney PJ, Whitaker AN. Fibrin crosslinks and lysis rates. Thromb Res 1979; 14: 85-94